Dissolving Facial volume treatment with Hyaluronidase

Patients arrive at hyaluronidase consultation through two very different doors. The first is patients who have had volume treatment in the past and have decided they want it gone, either because the result migrated, because the volume settled into a position they did not want, because they want to reset before any further treatment, or simply because they no longer want volume treatment in their face. The second is the much smaller group of patients who present with concerns suggesting a vascular event during or after recent volume treatment, where hyaluronidase is the emergency intervention.

The same product is used. The two conversations are entirely different.

What hyaluronidase is and how it works

Hyaluronidase is an enzyme that catalyses the breakdown of hyaluronic acid, the molecule that forms the basis of most modern facial volume treatment products. The enzyme exists naturally in the human body as part of normal connective tissue metabolism. The pharmaceutical grade enzyme used clinically is produced from defined biological sources and prescribed as a Schedule 4 medicine for specific clinical indications.

When injected into a region containing hyaluronic acid volume treatment, the enzyme acts within hours to days, breaking down the volume treatment structure into smaller fragments that the body then metabolises and excretes. The speed and completeness of dissolution depend on the volume of volume treatment present, the cross linking density of the original product, the time the volume treatment has been in place, and the dose of enzyme used. Some treatment products dissolve more easily than others. The enzyme does not affect non hyaluronic acid treatment products (such as calcium based or collagen stimulating volume treatments), which are not relevant to this discussion because they are not hyaluronic acid.

Planned dissolution: when patients ask for a reset

The most common indication for planned hyaluronidase is the patient who has accumulated volume treatment over years and has decided they want a reset. Sometimes the trigger is a specific feature: a lip that no longer looks like the lip the patient remembers, a cheek that has migrated downward over time, a tear trough region that has settled into a soft fullness rather than a refined contour. Sometimes it is the cumulative impression that the face no longer feels like the patient’s own. Either way, dissolution is an honest first step in reorganising the plan from where it currently sits.

The conversation begins with what the patient hopes the dissolution will achieve. Sometimes the answer is complete removal. Sometimes it is partial reduction in a specific region. Sometimes it is dissolution to baseline before considering whether to start fresh with a different plan. Each is clinically valid and each calls for different dosing and staging.

What planned dissolution involves practically

The treatment is performed in clinic. After consultation, written consent and patch testing where appropriate, the practitioner identifies the regions to be treated and places small volumes of the prescription enzyme directly into the volume treatment depots. Discomfort is comparable to volume treatment itself. The enzyme acts within hours, with the most visible reduction typically apparent at 24 to 48 hours. A single session may be sufficient for smaller volumes; larger or older volume treatment depots may require two or more sessions spaced two to four weeks apart.

Recovery from planned dissolution involves modest swelling and occasional bruising at injection points. Patients are advised to expect a transient phase where the area looks more swollen before it looks more normal. The settled appearance is usually evident at one to two weeks after the final session.

What patients often do not anticipate

Two practical points are worth naming because they sometimes surprise patients. The first is that dissolution can reveal anatomical change that has occurred underneath the volume treatment over the years it was in place. Skin texture, fat pad position and bone support all continue to change with time, and removing a long standing volume treatment depot sometimes exposes a face that has aged separately from the volume treatment that was masking it. The settled appearance after dissolution is the patient’s actual current anatomy, not the patient’s anatomy as it was when the volume treatment was first placed.

The second is that dissolution sometimes affects adjacent native hyaluronic acid in the tissue. The clinical effect is usually minor and recovers over weeks. Patients with very light volume treatment depots in regions of thin skin (under eye, lower lid) are sometimes advised that conservative dosing across two sessions is preferable to aggressive single session dissolution.

Vascular emergency: the second use of hyaluronidase

The other use of hyaluronidase is emergency management of vascular compromise during or after hyaluronic acid volume treatment. Vascular events occur when volume treatment is inadvertently placed within or compressing a facial artery, interrupting blood flow to the tissue served by that artery. The clinical signs include disproportionate pain at the injection site or in the territory served by the affected vessel, blanching or duskiness of the skin, mottling, and in serious cases the development of skin necrosis or, very rarely, ophthalmic complications.

The treatment is immediate, high dose hyaluronidase injected into and around the affected territory. The intent is to dissolve the offending volume treatment, restore blood flow and prevent tissue damage. This is a clinical emergency and the practice that performs volume treatment must be equipped to manage it: hyaluronidase available on site, the practitioner trained in vascular event recognition and management, and a clear protocol for escalation if the response is inadequate.

Why this changes how volume treatment should be considered

The existence of hyaluronidase as a reversal agent makes hyaluronic acid volume treatment one of the more controllable categories of aesthetic treatment medicine. Mistakes are correctable. Patient regret is recoverable. Vascular events, while rare, are manageable when caught early in a properly equipped practice. This is part of why hyaluronic acid volume treatment has become the dominant category in cosmetic practice, and part of why the relevant clinical question for a patient considering volume treatment is not just who will perform the treatment but who would manage it if something went wrong.

This question is one of the most useful single filters when evaluating a clinic. The practice that can articulate its complications protocol clearly, has hyaluronidase on site, and is staffed by practitioners trained in vascular event management is operating to the standard the patient should expect. The practice that cannot or does not is signalling something worth noting.

Why we do not name the prescription product

Australian regulation prohibits the advertising of Schedule 4 prescription medicines to the public. That includes hyaluronidase product names, the various treatment product brand names that hyaluronidase is used to dissolve, and the abbreviations and hashtags associated with all of these. The TGA has been increasingly active in enforcing this provision in the aesthetic treatments sector. We can talk in clinical detail about the mechanism, dose ranges, response profile and safety considerations of both volume treatment and the dissolving enzyme. We do not name brands or otherwise identify products to the public, because the law explicitly prohibits us from doing so.

Allergic reaction and patch testing

Hyaluronidase carries a small but recognised risk of allergic reaction, particularly in patients with a history of hymenoptera venom allergy. Patch testing prior to elective dissolution is standard practice in most clinics and is part of how the indication is approached at this clinic. In emergency management of vascular compromise, patch testing is bypassed because the urgency of the situation outweighs the small allergic reaction risk; this is consensus practice in international vascular event guidelines.

Other side effects are typically minor: bruising, transient swelling, brief tenderness. Significant adverse reactions are rare. Patients are given written aftercare and a direct contact for the practitioner if any concerns arise after the appointment.

AHPRA September 2025 considerations

The AHPRA guidelines for nonsurgical cosmetic procedures that came into force in September 2025 require an in person or video consultation with the prescribing practitioner each time a aesthetic treatment is prescribed. For elective dissolution of volume treatment, this requirement applies in the same way it applies to volume treatment itself. For emergency management of vascular events, the framework recognises that immediate intervention is the clinical priority and that prescribing decisions must support rapid response.

The September 2025 guidelines also reinforced the importance of explicit patient consent that includes the management plan for adverse events. Patients receiving volume treatment should know in advance whether and how hyaluronidase would be used if a complication occurred, and should know that the practitioner has the equipment and training to deliver it.

Conservative staging in elective dissolution

For elective dissolution of larger or older volume treatment depots, the C.O.R.E. Method approach is to stage treatment across two or more sessions spaced two to four weeks apart rather than attempting complete dissolution in a single session. The rationale is that staged dissolution allows the response to be evaluated at each step, the dose to be adjusted to the actual residual volume treatment, and the patient to experience the change gradually rather than as a single sudden shift.

Patients who arrive expecting same day complete dissolution sometimes find the staged approach slower than they had hoped. The clinical reasoning is that staged dissolution is more predictable, more comfortable, and more likely to settle into the configuration the patient actually wants. The two week interval between sessions also allows assessment of any rebound or migration that might inform the next dose.

Working with Corey

Corey Anderson is the only practitioner at Core Aesthetics. Registered with the Nursing and Midwifery Board of Australia since January 1996 (AHPRA NMW0001047575), Corey runs a one practitioner, low volume clinic in Oakleigh. For dissolution work in particular, the consistency of practitioner technique and the continuity of clinical record across years matters because patients who have had volume treatment elsewhere often arrive without complete records, and the assessment is partly forensic.

Patients see Corey at every visit. The clinic stocks hyaluronidase on site for both elective and emergency use. The complications protocol for volume treatment is articulated explicitly at consent for any patient receiving volume treatment.

What we do not claim

Three claims sometimes made about dissolution do not survive clinical scrutiny and we do not make them. The first is that dissolution will return the face to its pre volume treatment state. The face has aged in the years the volume treatment was in place; the post dissolution appearance is the current face, not the pretreatment face. The second is that dissolution is without risk. It carries the rare risks of allergic reaction, the common minor risks of bruising and transient swelling, and the small risk of affecting adjacent native tissue. The third is that any clinic can perform emergency vascular event management. Practices that perform volume treatment should be equipped for it; not all are.

Cost framing

Elective dissolution is priced on the actual product and time involved, quoted in writing as part of the consultation. Where staged sessions are anticipated, the written plan includes the realistic anticipated cost across all sessions. There is no surge pricing, no promotional pricing and no time limited offers. Emergency vascular event management for patients of the practice is part of the standard of care and is not separately billed in the conventional sense.

Booking a consultation

Dissolution consultations are individually scheduled. The first appointment is a clinical assessment, with no obligation to proceed in the same session. Where a complete dissolution plan involves staging across multiple sessions, the planning happens at the first consultation and the sessions are scheduled at intervals the patient chooses. Patients with concerns suggesting an active vascular event should contact the clinic urgently or, where appropriate, present to an emergency department.

Core Aesthetics operates from 12A Atherton Road, Oakleigh, in Melbourne south east. Booking is direct online or by contacting the clinic.

A note on patients arriving from elsewhere

Many patients seeking dissolution have had volume treatment at other clinics, sometimes years earlier, often without complete records of which products were used or in what volume. The consultation is partly forensic in these cases. We work through what the patient remembers about prior treatment, what is visible on examination, what the treatment plan would look like, and what the staging would involve. Patients sometimes find this conversation more substantive than the treatment itself, particularly if it is the first time anyone has taken time to walk through what is in their face and what the realistic options are.

This is a recognisable pattern in current cosmetic practice. The reversibility of hyaluronic acid volume treatment has changed the relationship patients have with treatment decisions. Patients who feel they made decisions in the past that they no longer agree with have a path back to baseline, and the conversation about that path is often where consultation based practice does its most useful work.

On the role of dissolution in Long-Term planning

For some patients, dissolution is the end of a chapter. For others, it is the start of a new conversation about what their face actually needs at this point in life, free from the carry over of decisions made years earlier. Both are legitimate outcomes and both are honoured at consultation. Where the patient wants to think it through after dissolution before making any further treatment decision, the consultation closes and the conversation can resume months later if and when the patient is ready.

On the broader clinical importance

Hyaluronidase is among the most important developments in modern aesthetic treatment practice. The reversibility it provides has reshaped both the patient conversation about volume treatment and the standard of care expected from clinics performing volume treatment. The patient considering volume treatment today has a different set of options and a different safety profile than the patient considering volume treatment twenty years ago. The clinic offering volume treatment today should articulate this clearly and operate within the standard the reversibility makes possible.

Volume treatment Dissolving Melbourne: Elective Correction Versus Urgent Care

Patients searching for volume treatment dissolving Melbourne may be looking for elective correction, a second opinion, or urgent help after a complication. These are different pathways. Elective dissolving is considered when volume treatment is unwanted, overfilled, migrated, irregular, or no longer consistent with the patient's anatomy. Urgent care is needed where there are signs of vascular compromise or other serious symptoms.

Core Aesthetics assesses volume treatment dissolving enquiries by timing, symptoms, treatment type if known, treatment history, and the area involved. Planned dissolving is not treated as a quick reset promise. It is a clinical decision with its own risks, swelling, review needs, and timing considerations.

Dissolving Under-eye treatment

Dissolving under-eye treatment requires particular care because the under eye area is thin, visible, and prone to swelling. Patients may seek dissolving because of puffiness, irregularity, Tyndall effect, persistent swelling, overcorrection, or a result that no longer suits the surrounding cheek and eye anatomy.

Assessment looks at whether the concern is actually volume treatment related, whether the product is likely to be hyaluronic acid, whether there is fluid tendency or malar oedema, and whether dissolving should be complete, partial, staged, or deferred. In some cases, the safer plan is review and monitoring before intervention. In others, dissolving may be appropriate before any future volume treatment is considered.

What To Expect After volume treatment Dissolving

After planned dissolving, swelling and temporary change are expected. The visible effect may begin within a short period, but the final assessment should not be rushed. Some patients need more than one appointment. Some need time for swelling to settle before deciding whether further dissolving or future treatment is appropriate.

The consultation explains the difference between dissolving product and restoring a previous face. Volume treatment may have been placed over changing anatomy, and the tissue may not look identical to an earlier baseline after dissolution. The aim is careful correction and reassessment, not an assured return to a specific past appearance.